Literature DB >> 25810313

On being less tolerant: enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation.

Alexander M Lesokhin1, Margaret K Callahan2, Michael A Postow2, Jedd D Wolchok2.   

Abstract

The recent approvals of two drugs that block the function of the immune checkpoint programmed cell death 1 (PD-1) have firmly planted tumor immunotherapy in the mainstream of clinical oncology. We provide a historical and immunologic context for these recent advances and discuss translational studies that provide insight into the efficacy of cancer immunotherapy at the individual patient level.
Copyright © 2015, American Association for the Advancement of Science.

Entities:  

Mesh：

Year:  2015        PMID： 25810313     DOI： 10.1126/scitranslmed.3010274

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN： 1946-6234            Impact factor:   17.956


  67 in total

Review 1.  Emerging cytokine networks in colorectal cancer.

Authors:  Nathan R West; Sarah McCuaig; Fanny Franchini; Fiona Powrie
Journal:  Nat Rev Immunol       Date:  2015-09-11       Impact factor: 53.106

2.  Cytomegalovirus vector expressing RAE-1γ induces enhanced anti-tumor capacity of murine CD8+ T cells.

Authors:  Tihana Tršan; Kristina Vuković; Petra Filipović; Ana Lesac Brizić; Niels A W Lemmermann; Kilian Schober; Dirk H Busch; William J Britt; Martin Messerle; Astrid Krmpotić; Stipan Jonjić
Journal:  Eur J Immunol       Date:  2017-07-04       Impact factor: 5.532

3.  Genetically Engineered Mouse Models of Pancreatic Cancer: The KPC Model (LSL-Kras(G12D/+) ;LSL-Trp53(R172H/+) ;Pdx-1-Cre), Its Variants, and Their Application in Immuno-oncology Drug Discovery.

Authors:  Jae W Lee; Chad A Komar; Fee Bengsch; Kathleen Graham; Gregory L Beatty
Journal:  Curr Protoc Pharmacol       Date:  2016-06-01

Review 4.  Clinical impact of tumour biology in the management of gastroesophageal cancer.

Authors:  Florian Lordick; Yelena Y Janjigian
Journal:  Nat Rev Clin Oncol       Date:  2016-03-01       Impact factor: 66.675

5.  Dendritic cell vaccine induces antigen-specific CD8+ T cells that are metabolically distinct from those of peptide vaccine and is well-combined with PD-1 checkpoint blockade.

Authors:  Koji Nagaoka; Akihiro Hosoi; Tamaki Iino; Yasuyuki Morishita; Hirokazu Matsushita; Kazuhiro Kakimi
Journal:  Oncoimmunology       Date:  2017-11-20       Impact factor: 8.110

Review 6.  Emerging roles of p53 and other tumour-suppressor genes in immune regulation.

Authors:  César Muñoz-Fontela; Anna Mandinova; Stuart A Aaronson; Sam W Lee
Journal:  Nat Rev Immunol       Date:  2016-09-26       Impact factor: 53.106

Review 7.  Lessons Learned from Checkpoint Blockade Targeting PD-1 in Multiple Myeloma.

Authors:  Alexander M Lesokhin; Susan Bal; Ashraf Z Badros
Journal:  Cancer Immunol Res       Date:  2019-08       Impact factor: 11.151

Review 8.  Regulatory circuits of T cell function in cancer.

Authors:  Daniel E Speiser; Ping-Chih Ho; Grégory Verdeil
Journal:  Nat Rev Immunol       Date:  2016-08-16       Impact factor: 53.106

9.  Ipilimumab reshapes T cell memory subsets in melanoma patients with clinical response.

Authors:  Joana Felix; Jérome Lambert; Marie Roelens; Eve Maubec; Hélène Guermouche; Cécile Pages; Irina Sidina; Debora J Cordeiro; Guitta Maki; François Chasset; Raphaël Porcher; Martine Bagot; Anne Caignard; Antoine Toubert; Céleste Lebbé; Hélène Moins-Teisserenc
Journal:  Oncoimmunology       Date:  2016-02-18       Impact factor: 8.110

Review 10.  Head and Neck Cancer Stem Cells: From Identification to Tumor Immune Network.

Authors:  L K Dionne; E R Driver; X J Wang
Journal:  J Dent Res       Date:  2015-08-07       Impact factor: 6.116
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.